Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06360133

Study of 5% VVN001 Ophthalmic Solution in Dry Eye Disease

This is a Phase 3, randomized, double-Masked, vehicle-controlled, multi-center study designed to evaluate the safety and efficacy of 5% VVN001 Ophthalmic Solution versus vehicle in Chinese subjects with dry eye disease.

Recruiting

Interested in participating?

Request Info

Key information

Age range

30 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Eye & Ent Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Location status: Recruiting

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provided written informed consent prior to any study-related procedures.
  • Are between 30 and 80 years of age.
  • Have a history of dry eye disease in both eyes.
  • Have been using artificial tears within 30 days of the screening visit
  • Have an Eye dryness score ≥50 (0-100 point VAS)
  • Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the following criteria in the study eye and the same eye at Visit 1 and Visit 2: 1) total CFS (tCFS) score ≥6; 2) any subregion CS score ≥2.5; 3) Schirmer score (without anesthesia) ≥1 and ≤7 mm/5 min.
  • Have a BCVA in the study eye of ≥4.3 (Standard for Logarithmic Visual Acuity Charts, 5-mark record).

Exclusion criteria

  • Have a known hypersensitivity or contraindication to the IP or components of IP.
  • Have history of uncontrolled glaucoma, IOP over 21 mmHg in either eye at the screening visit or are being treated with eye drops for glaucoma in the study eye. Or the subject has had laser or surgery for glaucoma in the study eye within 90 days of the study.
  • Woman of childbearing potential (WOCP) who are pregnant, lactating, or preparing for pregnant.

Treatment and study plan

VVN001 Ophthalmic Solution, 5%

Drug

VVN001 Ophthalmic Solution, 5%

VVN001 Ophthalmic Solution, Vehicle

Drug

VVN001 Ophthalmic Solution, Vehicle

Primary outcomes

  1. Corneal Fluorescein Staining

    Time frame: Day 84

    Mean Change from baseline (Visit 2) to Day84 (Visit 6) in total corneal fluorescein staining (tCFS) using modified NEI/Industry Workshop (0-4 scale, using 0.5 unit increments).

Secondary outcomes

  1. Eye Dryness

    Time frame: Day 84

    Mean Change from baseline (Visit 2) to Day 84 (Visit 6) in the individual symptom of eye dryness (0~100 VAS scale).

Study contacts

Contact information is provided by the study sponsor or research team.

Caroline Lu

CONTACT

[email protected]

86-18816562189

Sponsors and collaborators

Lead sponsor

VivaVision Biotech, Inc

Industry

Registry information

Official study title

A Phase 3, Randomized, Double-Masked, Vehicle-controlled, Multi-center Study Evaluating the Safety and Efficacy of 5% VVN001 in Chinese Subjects With Dry Eye Disease

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Apr 11, 2024
Registry last updated
Nov 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.